Suppr超能文献

两种用于检测炎症性肠病的自动粪便钙卫蛋白免疫测定法的分析和诊断性能

Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease.

作者信息

De Sloovere Maxime M W, De Smet Dieter, Baert Filip J, Debrabandere Johan, Vanpoucke Hilde J M

机构信息

.

出版信息

Clin Chem Lab Med. 2017 Aug 28;55(9):1435-1446. doi: 10.1515/cclm-2016-0796.

Abstract

BACKGROUND

We evaluated the (pre-)analytical and diagnostic performance of two automated fecal calprotectin (FC) immunoassays, Liaison® Calprotectin (Diasorin) on Liaison® XL and fCAL™ turbo (Bühlmann laboratories AG) on Cobas C501 (Roche Diagnostics), and compared it with our established Bühlmann ELISA method.

METHODS

Our study comprised 229 consecutive patients with clinical suspicion of inflammatory bowel disease (IBD).

RESULTS

All assay related stool extraction procedures showed excellent correlation with the established method, but the new stool extraction devices tend to give higher results as compared with stool weight methods. Both automated assays demonstrated good performance in terms of precision (CVt≤8.1%), accuracy (bias≤6.7%) and total error (≤16.4%). Method comparison with established enzyme linked immunosorbent assay (ELISA) showed good correlation (rs>0.925), but regression analysis showed significant proportional differences. Diagnostic performance characteristics with regard to diagnosis of IBD were good and in line with other reports. In addition, we were able to show that optimization of manufacturer's cut-off and moreover, the introduction of a gray zone resulted in a significant increase of post-test probability.

CONCLUSIONS

In conclusion, the newly developed stool extraction device protocols showed acceptable and comparable performance to the stool weight method. Overall, the automated Liaison® Calprotectin and fCAL™ turbo assay showed good analytical and diagnostic performance for detection of IBD.

摘要

背景

我们评估了两种粪便钙卫蛋白(FC)自动化免疫分析方法的(预)分析性能和诊断性能,即Liaison® XL平台上的Liaison®钙卫蛋白检测(索灵公司)以及Cobas C501(罗氏诊断公司)平台上的fCAL™ turbo检测(布尔曼实验室股份公司),并将其与我们已确立的布尔曼酶联免疫吸附测定(ELISA)方法进行比较。

方法

我们的研究纳入了229例临床怀疑患有炎症性肠病(IBD)的连续患者。

结果

所有与检测相关的粪便提取程序与既定方法均显示出极佳的相关性,但与粪便重量法相比,新型粪便提取装置的检测结果往往更高。两种自动化检测方法在精密度(CVt≤8.1%)、准确性(偏差≤6.7%)和总误差(≤16.4%)方面均表现良好。与既定的酶联免疫吸附测定(ELISA)方法进行方法比较显示出良好的相关性(rs>0.925),但回归分析显示存在显著的比例差异。IBD诊断的诊断性能特征良好,与其他报告一致。此外,我们能够证明,优化制造商的临界值,并且引入灰色区域会使检测后概率显著增加。

结论

总之,新开发的粪便提取装置方案显示出与粪便重量法相当且可接受的性能。总体而言,自动化的Liaison®钙卫蛋白检测和fCAL™ turbo检测在检测IBD方面显示出良好的分析和诊断性能。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验